
|Videos|October 19, 2018
Areas Under Investigation in Ph-Like ALL
Author(s)Sarah K. Tasian, MD
Sarah K. Tasian, MD, discusses what she finds most interesting about Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia.
Advertisement
Sarah K. Tasian, MD, attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses what she finds most interesting about Philadelphia chromosome (Ph-like) acute lymphoblastic leukemia (ALL).
Tasian is surprised by how heterogenous the disease is and how they are always discovering new fusions. Despite the number of lesions, she says patients have either 1 of 2 pathways:BCR-ABLor CRLF2-R/JAK.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5

































